A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.

Phase 1/Phase 2

Novartis Pharmaceuticals